Hello and welcome to the details of China’s Kintor says interim analysis of Covid treatment trial misses statistical criteria and now with the details
Nevin Al Sukari - Sana'a - BEIJING, Dec 27 — China’s Kintor Pharmaceutical Ltd said data from a Phase III clinical trial for its potential Covid-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.
“In a trial that had enrolled 384 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalisation was reported,” a Kintor representative said today.
The low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.
Kintor said in a filing today that it will seek consent from authorities, including US Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a Covid-19 vaccination. — Reuters
These were the details of the news China’s Kintor says interim analysis of Covid treatment trial misses statistical criteria for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
